News >

TNBC Paradigm Evolving With Intriguing Treatment Methods

Jessica Hergert
Published: Thursday, Nov 14, 2019

Tiffany A. Traina, MD

Tiffany A. Traina, MD
Novel approaches, including immunotherapy, antibody-drug conjugates (ADCs), androgen receptor (AR)–targeting agents, AKT inhibitors, and PARP inhibitors, are rapidly shifting the treatment paradigm in metastatic triple-negative breast cancer (TNBC), said Tiffany A. Traina, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication